On February 5, the Wuhan Virus Institute of the Chinese Academy of Sciences announced that the Wuhan Virus Research Institute of the Chinese Academy of Sciences/The Center for Biosecurity Research and the National Research Center for Emergency Prevention and Control drug Engineering and Technology of the Military Academy of Sciences conducted a joint study recently to make important progress in curbing the screening of the 2019 new coronavirus (2019-nCoV) drug.
(Original title: Why can Wuhan Virus Institute rush to declare Redsey’s invention patent? )
Origin of controversy:
The u.S. experimental drug Redsiewe’s patent was snapped up by Wuhan Virus Research Institute on January 21st.
“For Remdesivir, a drug that is not yet on the market in china and has intellectual property barriers, we filed a patent for Chinese invention (the use of a new type of coronavirus against 2019) on January 21st, in accordance with international practice and from the point of view of protecting the national interest, the article said. It will also enter major countries around the world through the PCT (Patent Cooperation Agreement). If foreign related enterprises intend to contribute to the prevention and control of China’s epidemic, we agree that in the case of national needs, do not require the implementation of the patent claims rights, hope to work together with foreign pharmaceutical companies for the outbreak prevention and control efforts. “
A number of senior pharmaceutical industry insiders to the first financial reporter analysis, Wuhan virus obtained is not a drug structure patents, nor drug synthesis patents, but a patent for the use of patents. The use of patents gilead will not apply. Because Redsiewe’s indications are currently only needed to be used extensively in outbreaks in China, Gilead itself does not have clinical resources.
“So imitation of Ridsiewe or the use of Redsiewe structure, active ingredient process type, all patents are still Gilead, in addition to the new coronavirus, this patent belongs to China, in fact, if China uses this product to treat the new coronavirus pneumonia, now does not violate the patent.” “If I were Gilead, I would give up this patent because it was so narrow that there was almost no market for this outbreak, ” the pharmaceutical industry insider told reporters. “
This person also pointed out that from a drug development and academic analysis, Redsiewe is one of a group of compounds patented by Gilead on July 22, 2010 to specifically inhibit RNA dependence RNA polymerase. RNA polymerases are the ones that coronaviruses need to multiply and amplify within cells, and inhibiting their enzyme activity can reduce viral replication. In previous studies, it has been proved that Redsiewe has inhibited the two coronaviruses SARS and MERS infected with human body, and now the research of Wuhan Virus Institute has also confirmed that the third coronavirus infected with human body- The drug has also completed pharmacokinetic studies and safety observations in human trials in previous development studies.
“So I think from a pharmacological point of view that there is a good chance that the drug will confirm the pharmacological effect of inhibiting the replication of new coronavirus in clinical studies of patients with neo-coronavirus pneumonia.” She said.
O’Shea, a pediatrician at Chibe Medical Services in Guangzhou, believes that in a state of emergency or in the public interest, even if there is patent protection, it can be compulsory. As long as Gilead does not apply to China, Wuhan Virus’s practice is legally infirm. It’s just that the writing doesn’t mention Gilead, and at this point it feels a little awkward.
She noted that, based on patent search, it was possible to determine that Gilead, the original research firm, had applied for or been granted at least 100 patents related to Redsey. Patent applications span 2011-2019. Gilead has also filed patent applications for coronavirus infection around compound structures, treatments and drug combinations. Developed by Gilead, Ridsywe was first used on January 26 this year to treat people with the new coronavirus infection, using infections such as the Ebola virus and Marburg virus.
In fact, in a statement released on January 31, Gilead and the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services (DHHS), the U.S. Centers for Disease Control and Prevention, the National Drug Administration (NMPA), Organizations such as the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), and researchers and clinicians are working together in the antiviral field we specialize in contributing to our expertise and resources to help patients and communities work together to combat 2019-nCoV.
In other words, the use of patent issues have been communicated with the relevant departments in advance, Wuhan virus does not exist inappropriate rush.
It is understood that Gilead is a well-known biopharmaceutical company focused on antiviral therapy, HIV and HCV (hepatitis C) treatment is a leader. They also developed the familiar anti-flu virus drug Tamiflu. In 1996, however, Gilead transferred production and sales rights to Roche.